Bladder Cancer, An Issue of Hematology/Oncology Clinics of North America, 1st Edition
Author :
Joaquim Bellmunt
This issue of Hematology/Oncology Clinics of North America, guest edited by Dr. Joaquin Bellmunt, is devoted to Bladder Cancer. Articles in this issue include: Diagnosis and Staging of Bladder Cancer; Epidemiology of Bladder Cancer; Molecular Biology ...view more
This issue of Hematology/Oncology Clinics of North America, guest edited by Dr. Joaquin Bellmunt, is devoted to Bladder Cancer. Articles in this issue include: Diagnosis and Staging of Bladder Cancer; Epidemiology of Bladder Cancer; Molecular Biology of Bladder Cancer; Pharmacogenomics in Bladder Cancer; Management of Non-muscle Invasive Bladder Cancer; Non-urothelial Bladder Cancer and Rare Variant Histologies; Management of UUT; New Trends in Surgical Management of Bladder Cancer; Bladder Preservation Strategies; Perioperative Therapy of Bladder Cancer (Neoadjuvant and Adjuvant); First Line Treatment and Prognostic Factors of Metastatic Disease: Platinum Eligible Patients; First Line Treatment of Metastatic Disease: Platinum Ineligible Patients; Salvage Therapy in Metastatic Disease; and Future Directions and Targeted Therapies in Bladder Cancer.
This issue of Hematology/Oncology Clinics of North America, guest edited by Dr. Joaquin Bellmunt, is devoted to Bladder Cancer. Articles in this issue include: Diagnosis and Staging of Bladder Cancer; Epidemiology of Bladder Cancer; Molecular Biology of Bladder Cancer; Pharmacogenomics in Bladder Cancer; Management of Non-muscle Invasive Bladder Cancer; Non-urothelial Bladder Cancer and Rare Variant Histologies; Management of UUT; New Trends in Surgical Management of Bladder Cancer; Bladder Preservation Strategies; Perioperative Therapy of Bladder Cancer (Neoadjuvant and Adjuvant); First Line Treatment and Prognostic Factors of Metastatic Disease: Platinum Eligible Patients; First Line Treatment of Metastatic Disease: Platinum Ineligible Patients; Salvage Therapy in Metastatic Disease; and Future Directions and Targeted Therapies in Bladder Cancer.
Author Information
By Joaquim Bellmunt, MD, PhD, Director, Bladder Cancer Center
Dana-Farber Cancer Institute
Dana-Farber/Brigham and Women's Cancer Center
Associate Professor, Harvard Medical School
https://www.us.elsevierhealth.com/bladder-cancer-an-issue-of-hematologyoncology-clinics-of-north-america-9780323359764.html1630Bladder Cancer, An Issue of Hematology/Oncology Clinics of North Americahttps://www.us.elsevierhealth.com/media/catalog/product/9/7/9780323359764.jpg64.3498.99USDInStock/Medicine/Hematology/Clinics/Clinics1374388725525504113841826925145120This issue of Hematology/Oncology Clinics of North America, guest edited by Dr. Joaquin Bellmunt, is devoted to Bladder Cancer. Articles in this issue include: Diagnosis and Staging of Bladder Cancer; Epidemiology of Bladder Cancer; Molecular Biology of Bladder Cancer; Pharmacogenomics in Bladder Cancer; Management of Non-muscle Invasive Bladder Cancer; Non-urothelial Bladder Cancer and Rare Variant Histologies; Management of UUT; New Trends in Surgical Management of Bladder Cancer; Bladder Preservation Strategies; Perioperative Therapy of Bladder Cancer (Neoadjuvant and Adjuvant); First Line Treatment and Prognostic Factors of Metastatic Disease: Platinum Eligible Patients; First Line Treatment of Metastatic Disease: Platinum Ineligible Patients; Salvage Therapy in Metastatic Disease; and Future Directions and Targeted Therapies in Bladder Cancer. This issue of Hematology/Oncology Clinics of North America, guest edited by Dr. Joaquin Bellmunt, is devoted to Bladder Cancer. Articles in this issue include: Diagnosis and Staging of Bladder Cancer; Epidemiology of Bladder Cancer; Molecular Biology of Bladder Cancer; Pharmacogenomics in Bladder Cancer; Management of Non-muscle Invasive Bladder Cancer; Non-urothelial Bladder Cancer and Rare Variant Histologies; Management of UUT; New Trends in Surgical Management of Bladder Cancer; Bladder Preservation Strategies; Perioperative Therapy of Bladder Cancer (Neoadjuvant and Adjuvant); First Line Treatment and Prognostic Factors of Metastatic Disease: Platinum Eligible Patients; First Line Treatment of Metastatic Disease: Platinum Ineligible Patients; Salvage Therapy in Metastatic Disease; and Future Directions and Targeted Therapies in Bladder Cancer.00add-to-cart97803233597642015ProfessionalBy Joaquim Bellmunt, MD, PhD20151Book152w x 229h (6.00" x 9.00")Elsevier0Apr 12, 2015IN STOCK - This may take up to 5 business days to shipBy <STRONG>Joaquim Bellmunt</STRONG>, MD, PhD, Director, Bladder Cancer Center
Dana-Farber Cancer Institute
Dana-Farber/Brigham and Women's Cancer Center
Associate Professor, Harvard Medical SchoolClinicsClinicsThe Clinics: Internal MedicineNoNoNoNoPlease SelectPlease SelectPlease Select
